Ultragenyx director sells shares, gets new equity grants

Q: What insider transactions did Ultragenyx (RARE) director Shehnaaz Suliman report?

She reported both equity awards and a sale. On May 14, 2026 she received RSUs and stock options, and on May 18, 2026 she sold 5,740 common shares in an open-market transaction while retaining a sizable direct holding.

Q: How many Ultragenyx (RARE) shares did director Shehnaaz Suliman sell and at what price?

She sold 5,740 common shares at $25.12 each. The transaction was coded as an open-market sale, and after completing it, her direct ownership position stood at 27,951 common shares of Ultragenyx Pharmaceutical Inc.

Q: What RSU grant did Ultragenyx (RARE) director Shehnaaz Suliman receive?

She received 7,751 Restricted Stock Units. The RSUs were granted under Ultragenyx’s 2023 Incentive Plan and are scheduled to vest in full on the earlier of the company’s next Annual Meeting of Stockholders or May 14, 2027.

Q: How many Ultragenyx (RARE) shares does director Shehnaaz Suliman own after the reported transactions?

She directly owns 27,951 common shares after the sale. This figure reflects her position following the May 18, 2026 open-market disposition of 5,740 shares reported in the Form 4 insider transaction filing.

Q: When will Shehnaaz Suliman’s new Ultragenyx (RARE) RSUs and options vest?

Both awards vest on the same schedule. The RSUs and stock options will vest in full on the earlier of Ultragenyx’s next Annual Meeting of Stockholders or May 14, 2027, aligning director compensation with future company milestones.

Ultragenyx Pharmaceutical Inc. director Shehnaaz Suliman reported a mix of equity awards and a share sale.

Accepted by SEC EDGAR 05/18/2026 - 06:41 PM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Ultragenyx Pharmaceutical Inc. director Shehnaaz Suliman reported a mix of equity awards and a share sale. On May 14, 2026, she received 7,751 Restricted Stock Units under the company’s 2023 Incentive Plan and a stock option for 14,058 shares with a $25.80 exercise price, both vesting in full on the earlier of the next Annual Meeting of Stockholders or May 14, 2027. On May 18, 2026, she executed an open-market sale of 5,740 shares of common stock at $25.12 per share, leaving her with 27,951 common shares held directly after the sale.

Insider Trade Summary 10b5-1

Net Seller: 5,740 shares

Net Sell 3 txns

Insider SULIMAN SHEHNAAZ

Role Director

Sold 5,740 shs ($144K)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,740	$25.12	$144K
Grant/Award	Stock Option (Right to Buy)	14,058	$0.00	$0.00
Grant/Award	Common Stock	7,751	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 14,058 contracts (Direct); Common Stock — 27,951 shares (Direct)

Footnotes (2)

F1. Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.
F2. The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.

Key Figures

Shares sold: 5,740 shares Sale price: $25.12/share Shares held after sale: 27,951 shares +5 more

8 metrics

Shares sold 5,740 shares Open-market sale on May 18, 2026

Sale price $25.12/share Open-market sale of common stock

Shares held after sale 27,951 shares Direct common stock ownership post-transaction

RSU grant size 7,751 units RSUs under 2023 Incentive Plan on May 14, 2026

Option grant 14,058 shares Stock Option (Right to Buy) granted May 14, 2026

Option exercise price $25.80/share Stock option strike price

Option expiration 2036-05-14 Expiration date of stock option grant

Vesting deadline May 14, 2027 Latest vesting date for RSUs and options

Key Terms

Restricted Stock Units ("RSUs"), 2023 Incentive Plan, Stock Option (Right to Buy), Annual Meeting of Stockholders, +1 more

5 terms

Restricted Stock Units ("RSUs") financial

"Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

2023 Incentive Plan financial

"Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan."

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Annual Meeting of Stockholders financial

"on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027."

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Ultragenyx (RARE) director Shehnaaz Suliman report?

She reported both equity awards and a sale. On May 14, 2026 she received RSUs and stock options, and on May 18, 2026 she sold 5,740 common shares in an open-market transaction while retaining a sizable direct holding.

How many Ultragenyx (RARE) shares did director Shehnaaz Suliman sell and at what price?

She sold 5,740 common shares at $25.12 each. The transaction was coded as an open-market sale, and after completing it, her direct ownership position stood at 27,951 common shares of Ultragenyx Pharmaceutical Inc.

What RSU grant did Ultragenyx (RARE) director Shehnaaz Suliman receive?

She received 7,751 Restricted Stock Units. The RSUs were granted under Ultragenyx’s 2023 Incentive Plan and are scheduled to vest in full on the earlier of the company’s next Annual Meeting of Stockholders or May 14, 2027.

What stock options were granted to Ultragenyx (RARE) director Shehnaaz Suliman?

She was granted options on 14,058 shares at a $25.80 strike. These stock options relate to Ultragenyx common stock and will vest in full on the earlier of the next Annual Meeting of Stockholders or May 14, 2027, with expiration in 2036.

How many Ultragenyx (RARE) shares does director Shehnaaz Suliman own after the reported transactions?

She directly owns 27,951 common shares after the sale. This figure reflects her position following the May 18, 2026 open-market disposition of 5,740 shares reported in the Form 4 insider transaction filing.

When will Shehnaaz Suliman’s new Ultragenyx (RARE) RSUs and options vest?

Both awards vest on the same schedule. The RSUs and stock options will vest in full on the earlier of Ultragenyx’s next Annual Meeting of Stockholders or May 14, 2027, aligning director compensation with future company milestones.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SULIMAN SHEHNAAZ

(Last)

(First)

(Middle)

C/O ULTRAGENYX PHARMACEUTICAL INC.

60 LEVERONI COURT

(Street)

NOVATO

CALIFORNIA

94949

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ultragenyx Pharmaceutical Inc. [ RARE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/14/2026		A		7,751⁽¹⁾	A	$0	33,691	D
Common Stock	05/18/2026		S		5,740	D	$25.12	27,951	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$25.8	05/14/2026		A		14,058		⁽²⁾	05/14/2036	Common Stock	14,058	$0	14,058	D

Explanation of Responses:

1. Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.

2. The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.

	/s/ Karah Parschauer, attorney-in-fact	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR